The North America Antiplatelet Market would witness market growth of 4.0% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 152.5 million Units, showcasing a growth of 2.8% (2019-2022).
A drug that inhibits thrombus formation and decreases platelet aggregation is considered an antiplatelet drug. They have a positive effect on the arterial circulation. They are frequently employed to prevent primary and secondary thrombotic cerebrovascular or cardiovascular disease. The prevention and treatment of antithrombotic drugs, which include anticoagulants, ischemic events, antiplatelet drugs, and thrombolytic drugs, are used for a wide range of indications. These include peripheral occlusion (PAO), venous thromboembolism (VTE), acute coronary syndrome (ACS), myocardial infarction (MI), and stroke.
Antiplatelet drugs lower the incidence of cardiovascular events like heart attacks and strokes. In clinical trials and research investigations, they help inhibit platelet aggregation and lower the formation of blood clots. These drugs' sustained use and market expansion are propelled by the positive outcomes associated with them. Enhanced awareness of cardiovascular disease risk factors and symptoms has enhanced diagnosis rates. The increased prevalence of routine screenings and early detection of these conditions are raising the demand for antiplatelet medications as preventative and therapeutic measures.
According to Centers for Disease Control and Prevention (CDC), in the United States, heart disease is the primary cause of death for men and women. In the United States, cardiovascular disease kills one person every 33 seconds. Approximately 695,000 individuals perished from heart disease in 2021, or one out of every five deaths. From 2018 to 2019, heart disease cost the United States roughly $239.9 billion annually. This includes the cost of health care services, medications, and productivity lost due to mortality. Consequently, the increase in cardiovascular disease prevalence drives the demand for antiplatelet medications to treat these conditions. Thus, owing to the aforementioned elements, the market will grow rapidly in the coming years.
The US market dominated the North America Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,473.5 Million by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
A drug that inhibits thrombus formation and decreases platelet aggregation is considered an antiplatelet drug. They have a positive effect on the arterial circulation. They are frequently employed to prevent primary and secondary thrombotic cerebrovascular or cardiovascular disease. The prevention and treatment of antithrombotic drugs, which include anticoagulants, ischemic events, antiplatelet drugs, and thrombolytic drugs, are used for a wide range of indications. These include peripheral occlusion (PAO), venous thromboembolism (VTE), acute coronary syndrome (ACS), myocardial infarction (MI), and stroke.
Antiplatelet drugs lower the incidence of cardiovascular events like heart attacks and strokes. In clinical trials and research investigations, they help inhibit platelet aggregation and lower the formation of blood clots. These drugs' sustained use and market expansion are propelled by the positive outcomes associated with them. Enhanced awareness of cardiovascular disease risk factors and symptoms has enhanced diagnosis rates. The increased prevalence of routine screenings and early detection of these conditions are raising the demand for antiplatelet medications as preventative and therapeutic measures.
According to Centers for Disease Control and Prevention (CDC), in the United States, heart disease is the primary cause of death for men and women. In the United States, cardiovascular disease kills one person every 33 seconds. Approximately 695,000 individuals perished from heart disease in 2021, or one out of every five deaths. From 2018 to 2019, heart disease cost the United States roughly $239.9 billion annually. This includes the cost of health care services, medications, and productivity lost due to mortality. Consequently, the increase in cardiovascular disease prevalence drives the demand for antiplatelet medications to treat these conditions. Thus, owing to the aforementioned elements, the market will grow rapidly in the coming years.
The US market dominated the North America Antiplatelet Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,473.5 Million by 2030. The Canada market is experiencing a CAGR of 6.4% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 5.5% during (2023 - 2030).
Based on Route of Administration, the market is segmented into Oral, and Injectable. Based on Drug Class, the market is segmented into Adenosine diphosphate (ADP) Receptor Inhibitors, Irreversible Inhibitors Cyclooxygenase, and Others. Based on Distribution Channel, the market is segmented into Drug store & Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cipla Limited, Glenmark Pharmaceuticals Limited, Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Eli Lilly And Company, Otsuka Pharmaceutical Co., Ltd., Sanofi S.A. , Lupin Limited and Chiesi Farmaceutici S.p.A.
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration (Volume, Million Units, USD Million, 2019-2030)- Oral
- Injectable
- Adenosine diphosphate (ADP) Receptor Inhibitors
- Irreversible Inhibitors Cyclooxygenase
- Others
- Drug store & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. North America Antiplatelet Market by Route of Administration
Chapter 5. North America Antiplatelet Market by Drug Class
Chapter 6. North America Antiplatelet Market by Distribution Channel
Chapter 7. North America Antiplatelet Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Glenmark Pharmaceuticals Limited
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Eli Lilly And Company
- Otsuka Pharmaceutical Co., Ltd.
- Sanofi S.A.
- Lupin Limited
- Chiesi Farmaceutici S.p.A
Methodology
LOADING...
